These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 29259743)

  • 1. Discovery of BI-2545: A Novel Autotaxin Inhibitor That Significantly Reduces LPA Levels in Vivo.
    Kuttruff CA; Ferrara M; Bretschneider T; Hoerer S; Handschuh S; Nosse B; Romig H; Nicklin P; Roth GJ
    ACS Med Chem Lett; 2017 Dec; 8(12):1252-1257. PubMed ID: 29259743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autotaxin inhibitors: a patent review (2012-2016).
    Nikolaou A; Kokotou MG; Limnios D; Psarra A; Kokotos G
    Expert Opin Ther Pat; 2017 Jul; 27(7):815-829. PubMed ID: 28447479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation.
    Gierse J; Thorarensen A; Beltey K; Bradshaw-Pierce E; Cortes-Burgos L; Hall T; Johnston A; Murphy M; Nemirovskiy O; Ogawa S; Pegg L; Pelc M; Prinsen M; Schnute M; Wendling J; Wene S; Weinberg R; Wittwer A; Zweifel B; Masferrer J
    J Pharmacol Exp Ther; 2010 Jul; 334(1):310-7. PubMed ID: 20392816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autotaxin and chronic inflammatory diseases.
    Magkrioti C; Galaris A; Kanellopoulou P; Stylianaki EA; Kaffe E; Aidinis V
    J Autoimmun; 2019 Nov; 104():102327. PubMed ID: 31471142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autotaxin in Pathophysiology and Pulmonary Fibrosis.
    Ninou I; Magkrioti C; Aidinis V
    Front Med (Lausanne); 2018; 5():180. PubMed ID: 29951481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of Potent Selective Nonzinc Binding Autotaxin Inhibitor BIO-32546.
    Ma B; Zhang L; Sun L; Xin Z; Kumaravel G; Marcotte D; Chodaparambil JV; Wang Q; Wehr A; Jing J; Hong VS; Wang T; Huang C; Shao Z; Mi S
    ACS Med Chem Lett; 2021 Jul; 12(7):1124-1129. PubMed ID: 34267882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis.
    Castelino FV; Bain G; Pace VA; Black KE; George L; Probst CK; Goulet L; Lafyatis R; Tager AM
    Arthritis Rheumatol; 2016 Dec; 68(12):2964-2974. PubMed ID: 27390295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and therapeutic potential of autotaxin small molecule inhibitors: From bench to advanced clinical trials.
    Matralis AN; Afantitis A; Aidinis V
    Med Res Rev; 2019 May; 39(3):976-1013. PubMed ID: 30462853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis.
    Black KE; Berdyshev E; Bain G; Castelino FV; Shea BS; Probst CK; Fontaine BA; Bronova I; Goulet L; Lagares D; Ahluwalia N; Knipe RS; Natarajan V; Tager AM
    FASEB J; 2016 Jun; 30(6):2435-50. PubMed ID: 27006447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and optimization of ATX inhibitors via modeling, synthesis and biological evaluation.
    Balupuri A; Lee MH; Chae S; Jung E; Yoon W; Kim Y; Son SJ; Ryu J; Kang DH; Yang YJ; You JN; Kwon H; Jeong JW; Koo TS; Lee DY; Kang NS
    Eur J Med Chem; 2018 Mar; 148():397-409. PubMed ID: 29477073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of autotaxin inhibitors: A series of zinc binding triazoles.
    Thomson CG; Le Grand D; Dowling M; Brocklehurst CE; Chinn C; Elphick L; Faller M; Freeman M; Furminger V; Gasser C; Hamadi A; Hardaker E; Head V; Hill JC; Janus DI; Pearce D; Poulaud AS; Stanley E; Sviridenko L
    Bioorg Med Chem Lett; 2018 Jul; 28(13):2279-2284. PubMed ID: 29798825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacologic targeting of the ATX/LPA axis attenuates bleomycin-induced pulmonary fibrosis.
    Ninou I; Kaffe E; Müller S; Budd DC; Stevenson CS; Ullmer C; Aidinis V
    Pulm Pharmacol Ther; 2018 Oct; 52():32-40. PubMed ID: 30201409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Autotaxin Inhibitors for the Treatment of Osteoarthritis Pain: Lead Optimization via Structure-Based Drug Design.
    Jones SB; Pfeifer LA; Bleisch TJ; Beauchamp TJ; Durbin JD; Klimkowski VJ; Hughes NE; Rito CJ; Dao Y; Gruber JM; Bui H; Chambers MG; Chandrasekhar S; Lin C; McCann DJ; Mudra DR; Oskins JL; Swearingen CA; Thirunavukkarasu K; Norman BH
    ACS Med Chem Lett; 2016 Sep; 7(9):857-61. PubMed ID: 27660691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S32826, a nanomolar inhibitor of autotaxin: discovery, synthesis and applications as a pharmacological tool.
    Ferry G; Moulharat N; Pradère JP; Desos P; Try A; Genton A; Giganti A; Beucher-Gaudin M; Lonchampt M; Bertrand M; Saulnier-Blache JS; Tucker GC; Cordi A; Boutin JA
    J Pharmacol Exp Ther; 2008 Dec; 327(3):809-19. PubMed ID: 18755937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computer Aided Drug Design Approaches for Identification of Novel Autotaxin (ATX) Inhibitors.
    Vrontaki E; Melagraki G; Kaffe E; Mavromoustakos T; Kokotos G; Aidinis V; Afantitis A
    Curr Med Chem; 2016; 23(17):1708-24. PubMed ID: 26997151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis.
    Desroy N; Housseman C; Bock X; Joncour A; Bienvenu N; Cherel L; Labeguere V; Rondet E; Peixoto C; Grassot JM; Picolet O; Annoot D; Triballeau N; Monjardet A; Wakselman E; Roncoroni V; Le Tallec S; Blanque R; Cottereaux C; Vandervoort N; Christophe T; Mollat P; Lamers M; Auberval M; Hrvacic B; Ralic J; Oste L; van der Aar E; Brys R; Heckmann B
    J Med Chem; 2017 May; 60(9):3580-3590. PubMed ID: 28414242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and optimization of boronic acid based inhibitors of autotaxin.
    Albers HM; van Meeteren LA; Egan DA; van Tilburg EW; Moolenaar WH; Ovaa H
    J Med Chem; 2010 Jul; 53(13):4958-67. PubMed ID: 20536182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autotaxin Implication in Cancer Metastasis and Autoimunne Disorders: Functional Implication of Binding Autotaxin to the Cell Surface.
    Peyruchaud O; Saier L; Leblanc R
    Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31906151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Potent
    Kawaguchi M; Okabe T; Okudaira S; Hama K; Kano K; Nishimasu H; Nakagawa H; Ishitani R; Kojima H; Nureki O; Aoki J; Nagano T
    J Med Chem; 2020 Mar; 63(6):3188-3204. PubMed ID: 32134652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening and X-ray crystal structure-based optimization of autotaxin (ENPP2) inhibitors, using a newly developed fluorescence probe.
    Kawaguchi M; Okabe T; Okudaira S; Nishimasu H; Ishitani R; Kojima H; Nureki O; Aoki J; Nagano T
    ACS Chem Biol; 2013 Aug; 8(8):1713-21. PubMed ID: 23688339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.